Oligoclonal Band Status and Features of Radiological and Clinical Findings in Patients with Multiple Sclerosis in Lithuania

Background and Objectives: Multiple sclerosis (MS) is a widely spread and debilitating disease with 2.8 million people worldwide currently affected. However, the exact pathogenesis of the disease and its progression remains incompletely understood. According to the revised McDonald criteria, cerebrospinal fluid oligoclonal bands (CSF OCBs) magnetic resonance imaging (MRI) results, in conjunction with clinical presentation, remain the gold standard of MS diagnostics. Therefore, this study aims to evaluate the association between CSF OCB status and features of radiological and clinical findings in patients with multiple sclerosis in Lithuania. Materials and Methods: The selection of 200 MS patients was performed in order to find associations between CSF OCB status, MRI data and various disease features. The data were acquired from outpatient records and a retrospective analysis was performed. Results: OCB positive patients were diagnosed with MS earlier and had spinal cord lesions more frequently than OCB negative patients. Patients with lesions in the corpus callosum had a greater increase in the Expanded Disability Status Scale (EDSS) score between their first and last visit. Patients with brainstem lesions had higher EDSS scores during their first and last visit. Even so, the progression of the EDSS score was not greater. The time between the first symptoms and diagnosis was shorter for patients who had juxtacortical lesions than patients who did not. Conclusions: CSF OCBs and MRI data remain irreplaceable tools when diagnosing multiple sclerosis as well as prognosing the development of the disease and disability.

[1]  L. Ramió-Torrentá,et al.  Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis. , 2022, Multiple sclerosis and related disorders.

[2]  Ovidijus Laucius,et al.  Factors Related to the Progression of Clinically Isolated Syndrome to Multiple Sclerosis: A Retrospective Study in Lithuania , 2022, Medicina.

[3]  Elif Söylemez,et al.  The Effect of Oligoclonal Bands in Patients with Multiple Sclerosis , 2022, Türk Nöroloji Dergisi.

[4]  E. Thouvenot,et al.  Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome , 2022, Frontiers in Immunology.

[5]  M. Magyari,et al.  Aging With Multiple Sclerosis: Age-Related Factors and Socioeconomic Risks , 2022, Frontiers in Neurology.

[6]  T. Shiner,et al.  Reinforcing the evidence of oligoclonal bands as a prognostic factor in patients with Multiple sclerosis. , 2021, Multiple sclerosis and related disorders.

[7]  B. Uitdehaag,et al.  MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis , 2021, Multiple sclerosis.

[8]  J. Newton,et al.  Cardiac Autonomic Dysfunction in Myasthenia Gravis and Relapsing-Remitting Multiple Sclerosis—A Pilot Study , 2021, Journal of clinical medicine.

[9]  J. Hillert,et al.  Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study , 2021, Scientific Reports.

[10]  C. Falup-Pecurariu,et al.  Autonomic dysfunctions in multiple sclerosis: Challenges of clinical practice (Review). , 2020, Experimental and Therapeutic Medicine.

[11]  M. Sormani,et al.  Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling , 2020, Multiple sclerosis.

[12]  E. Leray,et al.  Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition , 2020, Multiple sclerosis.

[13]  B. Combès,et al.  Prognostic value of spinal cord MRI in multiple sclerosis patients. , 2020, Revue neurologique.

[14]  A. Kermode,et al.  Advanced MRI features in relapsing multiple sclerosis patients with and without CSF oligoclonal IgG bands , 2020, Scientific Reports.

[15]  T. Vollmer,et al.  Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides , 2020, PloS one.

[16]  E. Celius,et al.  The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis , 2020, Multiple sclerosis journal - experimental, translational and clinical.

[17]  D. Arnold,et al.  Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis , 2019, Brain : a journal of neurology.

[18]  F. Barkhof,et al.  Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability? , 2019, Multiple sclerosis.

[19]  A. Kermode,et al.  Comparison of multiple sclerosis patients with and without oligoclonal IgG bands in South China , 2019, Journal of Clinical Neuroscience.

[20]  O. Ciccarelli,et al.  Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines , 2019, Brain : a journal of neurology.

[21]  R. Bakshi,et al.  Magnetic Resonance Imaging in Multiple Sclerosis. , 2018, Cold Spring Harbor perspectives in medicine.

[22]  T. Akaishi,et al.  Oligoclonal bands and periventricular lesions in multiple sclerosis will not increase blood-brain barrier permeability , 2018, Journal of the Neurological Sciences.

[23]  H. Siebner,et al.  Disability in progressive MS is associated with T2 lesion changes. , 2018, Multiple sclerosis and related disorders.

[24]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[25]  À. Rovira,et al.  Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis , 2015, American Journal of Neuroradiology.

[26]  Neeta Garg,et al.  An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis , 2015, Brain and behavior.

[27]  David H. Miller,et al.  Spinal cord MRI in multiple sclerosis—diagnostic, prognostic and clinical value , 2015, Nature Reviews Neurology.

[28]  Ludwig Kappos,et al.  Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis , 2015, Neurology.

[29]  E. Eren,et al.  Comparison of neurophysiological and MRI findings of patients with multiple sclerosis using oligoclonal band technique , 2013, Annals of neurosciences.

[30]  M. Sormani,et al.  MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials , 2013, The Lancet Neurology.

[31]  H. Tremlett,et al.  Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression , 2013, Multiple sclerosis.

[32]  G. Giovannoni,et al.  Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  J. Hillert,et al.  Impact of cerebrospinal-fluid oligoclonal immunoglobulin bands and HLA-DRB1 risk alleles on brain magnetic-resonance-imaging lesion load in Swedish multiple sclerosis patients , 2013, Journal of Neuroimmunology.

[34]  A. Damasceno,et al.  Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients , 2012, Multiple sclerosis.

[35]  N. Kale,et al.  Electrophysiological and clinical correlates of corpus callosum atrophy in patients with multiple sclerosis , 2010, Neurological research.

[36]  P. Sørensen,et al.  The changing demographic pattern of multiple sclerosis epidemiology , 2010, The Lancet Neurology.

[37]  L. Roccatagliata,et al.  MR peri‐CSF lesions and CSF oligoclonal bands in Italian multiple sclerosis patients , 2009, Acta neurologica Scandinavica.

[38]  W. Valdar,et al.  Sex ratio of multiple sclerosis in Canada: a longitudinal study , 2006, The Lancet Neurology.

[39]  Rohit Bakshi,et al.  The measurement and clinical relevance of brain atrophy in multiple sclerosis , 2006, The Lancet Neurology.

[40]  Jonathan Taylor,et al.  Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets , 2003, NeuroImage.

[41]  E. Leray,et al.  Epidemiology of multiple sclerosis. , 2016, Revue neurologique.